Table 6.
Effectiveness outcomes
| Baseline (n = 29) | 3-mo follow-up (n = 25) | 6-mo follow-up (n = 21) | 12-mo follow-up (n = 17) | |
|---|---|---|---|---|
| NT-proBNP (pg/mL) | 1005.9 (894, 1294) | 806.0 (670, 1032) | 697.0 (623, 861) | 705.0 (631, 908) |
| KCCQ OSS (points) | 41.4 ± 12.7 | 48.3 ± 12.4 | 53.8 ± 12.0 | 58.3 ± 10.1 |
| 6MWD (m) | 216.0 ± 43.7 | 266.9 ± 46.6 | 298.6 ± 61.8 | 303.3 ± 61.8 |
| LVEF (%) | 34.7 ± 2.9 | 38.0 ± 3.5 | 39.1 ± 3.3 | 40.5 ± 3.6 |
| NYHA class | 29 (100%) class III | 8 (32%) class II 17 (68%) class III |
11 (52%) class II 10 (48%) class III |
11 (65%) class II 6 (35%) class III |
Data is displayed as mean ± standard deviation or median with interquartile ranges (Q1, Q3), depending on data distribution.
KCCQ OSS, Kansas City Cardiomyopathy Questionnaire overall summary score; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal-pro-B-type natriuretic peptide; NYHA, New York Heart Association; 6MWD, 6-min hall walk distance.